Switch to:
Also traded in: Australia, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GENE's Cash to Debt is ranked higher than
100% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. GENE: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GENE' s Cash to Debt Range Over the Past 10 Years
Min: 1.13  Med: 45.1 Max: No Debt
Current: No Debt
Equity to Asset 0.89
GENE's Equity to Asset is ranked higher than
92% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. GENE: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
GENE' s Equity to Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.78 Max: 0.92
Current: 0.89
0.27
0.92
F-Score: 3
Z-Score: -4.51
M-Score: -2.09
WACC vs ROIC
28.51%
-963.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -793.07
GENE's Operating margin (%) is ranked lower than
90% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. GENE: -793.07 )
Ranked among companies with meaningful Operating margin (%) only.
GENE' s Operating margin (%) Range Over the Past 10 Years
Min: -793.07  Med: -94.68 Max: 6.75
Current: -793.07
-793.07
6.75
Net-margin (%) -751.91
GENE's Net-margin (%) is ranked lower than
89% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. GENE: -751.91 )
Ranked among companies with meaningful Net-margin (%) only.
GENE' s Net-margin (%) Range Over the Past 10 Years
Min: -751.91  Med: -92.71 Max: 4.93
Current: -751.91
-751.91
4.93
ROE (%) -54.20
GENE's ROE (%) is ranked lower than
72% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. GENE: -54.20 )
Ranked among companies with meaningful ROE (%) only.
GENE' s ROE (%) Range Over the Past 10 Years
Min: -271.23  Med: -52.78 Max: 14.99
Current: -54.2
-271.23
14.99
ROA (%) -49.54
GENE's ROA (%) is ranked lower than
72% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. GENE: -49.54 )
Ranked among companies with meaningful ROA (%) only.
GENE' s ROA (%) Range Over the Past 10 Years
Min: -134.56  Med: -45.72 Max: 10.58
Current: -49.54
-134.56
10.58
ROC (Joel Greenblatt) (%) -1379.71
GENE's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. GENE: -1379.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GENE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2298.65  Med: -535.14 Max: 65.76
Current: -1379.71
-2298.65
65.76
Revenue Growth (3Y)(%) -61.10
GENE's Revenue Growth (3Y)(%) is ranked lower than
94% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. GENE: -61.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GENE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -3.65 Max: 39.5
Current: -61.1
0
39.5
EBITDA Growth (3Y)(%) -37.00
GENE's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. GENE: -37.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GENE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -6.55 Max: 31
Current: -37
0
31
EPS Growth (3Y)(%) -37.00
GENE's EPS Growth (3Y)(%) is ranked lower than
84% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. GENE: -37.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GENE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.25 Max: 37.5
Current: -37
0
37.5
» GENE's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-08-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

GENE Guru Trades in Q4 2015

Jim Simons 317,480 sh (-17.28%)
» More
Q1 2016

GENE Guru Trades in Q1 2016

Jim Simons 314,380 sh (-0.98%)
» More
Q2 2016

GENE Guru Trades in Q2 2016

Jim Simons 403,480 sh (+28.34%)
» More
Q3 2016

GENE Guru Trades in Q3 2016

Jim Simons 486,680 sh (+20.62%)
» More
» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414    SIC: 2836
Compare:NAS:BIOC, NAS:CAPN, OTCPK:VRTT, NAS:HTGM, NAS:DRIO, NAS:APPY, NAS:ROSG, OTCPK:MNLIF, NAS:ROKA, OTCPK:MDIT, NAS:ATOS, NAS:CBMX, NAS:SGNL, OTCPK:LEDIF, NAS:TBIO, OTCPK:BTHCF, OTCPK:MHTX, NAS:BASI, OTCPK:MYAN, NAS:IDXG » details
Traded in other countries:GTG.Australia, GNTLF.USA,
Genetic Technologies Ltd is a molecular diagnostics company. It offers predictive testing 7 assessment tools to help physicians manage women's health.

Genetic Technologies Ltd is incorporated in Australia on January 05, 1987. The Company is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.

Ratios

vs
industry
vs
history
P/B 1.39
GENE's P/B is ranked higher than
84% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. GENE: 1.39 )
Ranked among companies with meaningful P/B only.
GENE' s P/B Range Over the Past 10 Years
Min: 0.7  Med: 2.86 Max: 23.33
Current: 1.39
0.7
23.33
EV-to-EBIT -0.86
GENE's EV-to-EBIT is ranked lower than
99.99% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. GENE: -0.86 )
Ranked among companies with meaningful EV-to-EBIT only.
GENE' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.9  Med: -2.4 Max: 133.8
Current: -0.86
-40.9
133.8
EV-to-EBITDA -0.87
GENE's EV-to-EBITDA is ranked lower than
99.99% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. GENE: -0.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
GENE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.8  Med: -2.5 Max: 164.8
Current: -0.87
-40.8
164.8
Current Ratio 9.11
GENE's Current Ratio is ranked higher than
92% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. GENE: 9.11 )
Ranked among companies with meaningful Current Ratio only.
GENE' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.87 Max: 11.28
Current: 9.11
1.08
11.28
Quick Ratio 8.98
GENE's Quick Ratio is ranked higher than
92% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. GENE: 8.98 )
Ranked among companies with meaningful Quick Ratio only.
GENE' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.17 Max: 11.09
Current: 8.98
1.04
11.09
Days Inventory 79.26
GENE's Days Inventory is ranked higher than
54% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. GENE: 79.26 )
Ranked among companies with meaningful Days Inventory only.
GENE' s Days Inventory Range Over the Past 10 Years
Min: 21.15  Med: 108.56 Max: 118.88
Current: 79.26
21.15
118.88
Days Sales Outstanding 127.51
GENE's Days Sales Outstanding is ranked lower than
87% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. GENE: 127.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
GENE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.06  Med: 34.6 Max: 127.51
Current: 127.51
13.06
127.51
Days Payable 192.57
GENE's Days Payable is ranked higher than
84% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. GENE: 192.57 )
Ranked among companies with meaningful Days Payable only.
GENE' s Days Payable Range Over the Past 10 Years
Min: 62.36  Med: 178.73 Max: 357.55
Current: 192.57
62.36
357.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.40
GENE's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. GENE: -53.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GENE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -54.5  Med: -7.2 Max: 0
Current: -53.4
-54.5
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.97
GENE's Price/Net Cash is ranked higher than
99% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.60 vs. GENE: 0.97 )
Ranked among companies with meaningful Price/Net Cash only.
GENE' s Price/Net Cash Range Over the Past 10 Years
Min: 0.93  Med: 11.33 Max: 50
Current: 0.97
0.93
50
Price/Net Current Asset Value 0.97
GENE's Price/Net Current Asset Value is ranked higher than
98% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. GENE: 0.97 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GENE' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.93  Med: 6 Max: 50
Current: 0.97
0.93
50
Price/Tangible Book 0.97
GENE's Price/Tangible Book is ranked higher than
87% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. GENE: 0.97 )
Ranked among companies with meaningful Price/Tangible Book only.
GENE' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.93  Med: 8.78 Max: 40
Current: 0.97
0.93
40
Earnings Yield (Greenblatt) (%) -119.34
GENE's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. GENE: -119.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GENE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -133.26  Med: 2 Max: 3.5
Current: -119.34
-133.26
3.5

More Statistics

Revenue (TTM) (Mil) $0.82
EPS (TTM) $ -0.54
Beta2.75
Short Percentage of Float1.21%
52-Week Range $1.12 - 3.25
Shares Outstanding (Mil)11.44
» More Articles for GENE

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Genetic Technologies Launches ADS Offering (GENE) Dec 02 2016
Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares Dec 01 2016
Genetic Technologies In Colorectal Cancer Pact (GENE) Nov 30 2016
Genetic Technologies Practically Doubles on Licensing Agreement Nov 29 2016
Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License... Nov 29 2016
Annual General Meeting Results Nov 23 2016
2016 Annual General Meeting Presentation Nov 23 2016
GENETIC TECHNOLOGIES LTD Financials Nov 03 2016
Notice of 2016 Annual General Meeting and Sample Proxy Oct 24 2016
Genetic Technologies Launches BREVAGenplus(R) Marketing Program Around Susan G. Komen(R)'s Race for... Oct 03 2016
Genetic Technologies Ltd. :GENE-US: Earnings Analysis: For the six months ended June 30, 2016 :... Sep 30 2016
Genetic Technologies Ltd. :GENE-US: Earnings Analysis: 2016 By the Numbers : September 23, 2016 Sep 23 2016
Appendix 4G and Corporate Governance Statement 2016 Aug 30 2016
Appendix 4E & Financial Report 2016 Aug 30 2016
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus(R) Marketing... Jun 22 2016
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann Update BREVAGenplus® Marketing... Jun 22 2016
Genetic Technologies Announces Appointment of Senior Medical Director Jun 21 2016
Appointment of Senior Medical Director Jun 21 2016
Genetic Technologies Limited (Nasdaq: GENE) to Ring The Nasdaq Stock Market Closing Bell May 05 2016
Genetic Technologies and Verizon IndyCar Series Driver Pippa Mann to Ring Nasdaq Stock Market... May 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)